Delivered-To: tjphuhs@gmail.com Received: by 2002:a05:6000:c0f:b0:435:ab39:4520 with SMTP id dn15csp202628wrb; Wed, 28 Jan 2026 15:03:38 -0800 (PST) X-Received: by 2002:a05:6214:dc4:b0:894:6888:bb4b with SMTP id 6a1803df08f44-894cc808922mr110891096d6.17.1769641418102; Wed, 28 Jan 2026 15:03:38 -0800 (PST) ARC-Seal: i=1; a=rsa-sha256; t=1769641418; cv=none; d=google.com; s=arc-20240605; b=L9jZi9jJcnSTnLwGJVYKIy67F7/aSF+tuQE3x0wpj+e8pc+c2Y8Jn94JsXo3fyfqPF Ojc0xKGhfSB9qPPxrrWE5B6I7yZyJ9bKf+sSVAEhaVkIlXoCJx1di98u7qF0NQOJT19A 5gTJDw3fPxL25/WYbBjlBsMpvAU83NsDJVbad7E0rxSCimQxSeMJEHHzUle6LwZzc3qi 4HzNsFLYpaHl00GVaZIhnzU/IEx0ZhZrlTFnmeg7ro8UTzM0JTd+knozKVDB0mwjR0Tp 4iGAVcum/SHZlDgPn5o/+2qOGJ/bmuVLnxOSi/Prz2e6SjBp2QDaI60fpHGmj06eoNLt /CQg== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:date:mime-version:sid:subject:reply-to :list-unsubscribe-post:list-unsubscribe:from:feedback-id:to :dkim-signature:dkim-signature; bh=fD6nataqfyOb4HjJ50lcoCFmDEQ7ou9JkZ6f2P/rrUU=; fh=Hcu5VqhndQNvtVhwbc8tr7JrSOSQJms/+lG2L+E9gBs=; b=iD2eKfK5iQy3VmP0fIDJFGT3Y/IEdhA9j7jTW4Du6fFLT/Gl2B1S5GPVijMBbIwkPe +2a22LOJISeyeB4yD1gW214K+jisjmkv0DGmAbo/Hh18Q6fcgBl3WcuXFMMQCFzpzkbI Az1kUUpoqKNBAvIRI1mWmlQ9EWuKCsG1elKt+5gBsioWJBt5Vt+6pHZXyfC3JT2mJ13q 53Dj4b0OKfeZJ5qjujy+K1JxBGRaPrHdb+iPNaqyzhkYug1M+O62HGcH7M0W9axFu6cy gMc92wr1jfdYjCaROxWtJ8EydVohXaBAD2cw5VOM39tQRcLTvEr7WfNq5SPGUWVxoEjp Wz3w==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=W5jB2cE5; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=EdBSnPD8; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.21 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com Return-Path: Received: from bh186-21.smtp-out.beehiivmail.net (bh186-21.smtp-out.beehiivmail.net. [69.67.186.21]) by mx.google.com with ESMTPS id 6a1803df08f44-894d385a78esi51854596d6.664.2026.01.28.15.03.37 for (version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256); Wed, 28 Jan 2026 15:03:38 -0800 (PST) Received-SPF: pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.21 as permitted sender) client-ip=69.67.186.21; Authentication-Results: mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=W5jB2cE5; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=EdBSnPD8; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.21 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com X-BmtaRef: eyJfQF8iOiJcXF8vIiwicmVjaXBpZW50IjoidGpwaHVoc0BnbWFpbC5jb20iLCJ4X2xpc3RfaWQiOiJmZDQxNjMwZS1lOTFmLTQ2ZDktYTI3NC1iNzQwZGFiNzU2ZDIiLCJ4X3N1YnNjcmliZXJfaWQiOiI5YzQwZDYzOS02ZTFkLTQyOTItYTlkNy0wZTRjYmJiNWQ1ZGIifQ== DKIM-Signature: v=1; a=rsa-sha256; d=bhmta.beehiiv.com; s=bh; c=relaxed/relaxed; bh=fD6nataqfyOb4HjJ50lcoCFmDEQ7ou9JkZ6f2P/rrUU=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1769641417; b=W5jB2cE5jcFsdha0E4GR5SwLRVmj/n9Go3UDbTuk7Wryln3RdQsZkwP/wX8Gi9Q2XyF8uJrac cMZjF+2yos5EfOTcinxi9SAtWy3VIvGXYXTD/Yn5SnfwVZyGbm9cKwfY17sRgAg7sM5qW+Ko3ba Vwa6aoYc6qL1kgEXWGorKJJnhnoO6orOlvB+ETx67bmoNeDCy7yDTVRUPg/v00VqW90vhmSzF9O Xt3wVnW7SjkFBTVKHAA8zAL8IMQEPa6uV7WJZWhjknb/NaLzKdMA1HFA2ahokpWtfCsOv5x7h89 cd+9lCo3iXTDpkR5gCt3tSEsfpwxtoDp0WNX7p8q0aNA==; DKIM-Signature: v=1; a=rsa-sha256; d=mail.beehiiv.com; s=bh; c=relaxed/relaxed; bh=fD6nataqfyOb4HjJ50lcoCFmDEQ7ou9JkZ6f2P/rrUU=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1769641417; b=EdBSnPD8KEcw2ta+DPpT70k6RYjip5ycIjs2CQBjKuF5BprOOFm/cs8ycGAiWOBbdsaNAct7d 3+O77NNbpctCta9cJWdnrHFZKN+2Qz0WAp6+9YLR/X/wFroVBeKTZYHeBHDx+7Tydr76Ay68Ue+ PBJe0szLBTsuy6wS7nawp96WUQ5StvJCcNkESYWJo8gw1mexf4wIndiEqTV/um9f2KuonoL4cqm 2SXPG1SPrZwJ5CSJKTcN7Fvns1ZeWk0qxmPAOwPUQ8vGAVNhTYjFCn//BF/G9PX3PQsDfBQNsvY D+ziPPJo+OhqFYTfFSmMVrTajriDQ454IE4YvOJw2Ulg==; Received: from mail.beehiiv.com by bhmta(mta8) with HTTP id <94428ea1fc9d11f0bfd20affc850261d> for ; Wed, 28 Jan 2026 23:03:37 +0000 Content-Type: multipart/alternative; boundary="KwbjSenxTCmGujA63/o4UA" To: "tjphuhs@gmail.com" Feedback-ID: f7204cf5-cd8a-4a7d-9097-af191f0aa5e1:newsletter:fd41630e-e91f-46d9-a274-b740dab756d2:c8f61fda6a60803 From: Hunter Williams List-Unsubscribe: , List-Unsubscribe-Post: List-Unsubscribe=One-Click Reply-To: Hunter's Health Hacks Subject: Men vs. Women Peptide Dosing X-Subscriber-ID: 9c40d639-6e1d-4292-a9d7-0e4cbbb5d5db sId: fd41630e-e91f-46d9-a274-b740dab756d2 x-beehiiv-ids: {"account_name":"https://huntershealthhacks.beehiiv.com/","campaign_id":"f7204cf5-cd8a-4a7d-9097-af191f0aa5e1","category":"newsletter","email_generated_at":1769641414,"user_id":"fd41630e-e91f-46d9-a274-b740dab756d2"} x-beehiiv-type: newsletter x-list-id: fd41630e-e91f-46d9-a274-b740dab756d2 x-list-owner: x-newsletter: https://huntershealthhacks.beehiiv.com/p/men-vs-women-peptide-dosing x-newsletter-id: https://huntershealthhacks.beehiiv.com/ x-newsletter-signup: https://huntershealthhacks.beehiiv.com/subscribe Mime-Version: 1.0 Date: Wed, 28 Jan 2026 23:03:37 +0000 Message-ID: <20260128.230337.b50f5ed8@mta8> --KwbjSenxTCmGujA63/o4UA Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Happy Wednesday!=0A=0AToday, I will address a question I get pretty regular= ly from readers.=0A=0A=E2=80=9CHunter, why do peptide protocols always seem= to use the same dose for men and women? Shouldn=E2=80=99t a 220-pound guy = take way more than a 130-pound woman?=E2=80=9C =E2=80=94 =0A=0ATotally fair= question, because we=E2=80=99ve all been trained to think dosing =3D body = size. =0A=0AAnd for some things, that=E2=80=99s true.=0A=0ABut peptides pla= y by a different set of rules than most people realize.=0A=0AMost peptides = aren=E2=80=99t =E2=80=9Creplacement=E2=80=9D therapies the way testosterone= , estrogen, progesterone, or thyroid hormone are. =0A=0AHormones are more l= ike the gas in your fuel tank, whereas peptides are more like tune-ups for = every other area of your car.=0A=0AThey bind to receptors, activate a signa= l, and trigger downstream cascades. Once you understand that, the unisex do= sing makes a lot more sense.=0A=0ASo today, I=E2=80=99ll break down the rea= l reason protocols often look identical across men and women, and then I=E2= =80=99ll give you the exceptions so you don=E2=80=99t walk away thinking it= =E2=80=99s always one-size-fits-all.=0A=0A=E2=80=9CFYI, [BioLongevity Labs]= (https://biolongevitylabs.com/) is having a sale. You can get 30% off all p= roducts and an extra 15% off with code HUNTERW.=E2=80=9C =E2=80=94 =0A=0A= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=0A=0A**Receptors**=0A=0AA GLP-1 receptor doesn=E2=80=99t= have a male version and a female version. =0A=0AA ghrelin receptor doesn= =E2=80=99t change because someone has higher estrogen. =0A=0AThe =E2=80=9Cl= ock and key=E2=80=9D is the lock and key. =0A=0AThat=E2=80=99s why drugs li= ke retatrutide are dosed the same way in men and women in the real world, e= ven though outcomes can differ slightly (women often lose a bit more weight= on average). =0A=0AThat difference isn=E2=80=99t usually fixed by changing= the dose. It=E2=80=99s more about differences in physiology, appetite sign= aling, and how body composition shifts over time. =0A=0ASame story with gro= wth-hormone secretagogues. =0A=0AWhen you activate that pathway, you=E2=80= =99re telling the pituitary to do what it already knows how to do. Men and = women both have that machinery. =0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Thresholds= **=0A=0AThis is where people get tripped up. With a lot of peptides, you re= ach an effective threshold where receptors are meaningfully activated, and = the cascade is turned on. =0A=0AAfter that, you get diminishing returns fas= t. More peptide doesn=E2=80=99t always mean more benefit. =0A=0ASometimes i= t just means more side effects, more water retention, more appetite changes= , more cost, more noise.=0A=0AThat=E2=80=99s why =E2=80=9Cstandard=E2=80=9D= protocols tend to cluster around similar mcg or mg ranges. =0A=0AThey=E2= =80=99re trying to hit a practical sweet spot.=0A=0AStrong enough to create= a biological shift, conservative enough to avoid running the pathway too h= ard.=0A=0AYou can see this logic in clinical research too. =0A=0AIn the MK-= 677 trial in older adults, a single daily dose was used, growth hormone/IGF= -1 levels rose, and fat-free mass improved over time, without splitting the= protocol into =E2=80=9Cmen=E2=80=99s dosing=E2=80=9D and =E2=80=9Cwomen=E2= =80=99s dosing.=E2=80=9D =0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Pharmacokinetics= **=0A=0AMany people assume that women and men metabolize substances differe= ntly. =0A=0ASometimes that=E2=80=99s true with specific oral drugs, especia= lly when liver enzyme differences matter. =0A=0ABut most popular peptides a= re injected (or nasal), and they=E2=80=99re cleared by pathways that don=E2= =80=99t reliably split by sex in a way that forces dosing differences.=0A= =0AInstead, what matters more is stuff like:=0A=0A* injection route and fre= quency=0A=0A* the half-life of the compound=0A=0A* kidney function=0A=0A* b= ody fat vs lean mass distribution=0A=0A* how sensitive the person is to the= downstream effect (nausea on GLP-1s, edema on GH pathways, etc.)=0A=0APept= ide dosing has general =E2=80=9Cparameters=E2=80=9D for both men and women,= and then you adjust based on response. =0A=0AThat=E2=80=99s why you=E2=80= =99ll see slow titrations and conservative ramps in the real world, especia= lly with GLP-1s and anything that touches GH/IGF-1.=0A=0AAnd again, the cli= nical data supports the idea that outcomes can differ by sex while the dosi= ng protocol stays the same.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Use Cases**=0A= =0AInjury repair peptides like BPC-157 are a perfect example. =0A=0AThe pro= posed mechanism is broadly pro-healing via growth factors, angiogenesis sig= naling, inflammation modulation, and tissue remodeling. =0A=0AAnd the best = human data we have is still limited, but a systematic review covering the b= roader evidence base notes a small human knee pain series alongside many an= imal models, with no indication that =E2=80=9Cfemale tissue needs a differe= nt dose.=E2=80=9D =0A=0AImmune peptides are the same concept. =0A=0AThymosi= n alpha-1 is used clinically as an immunomodulator, interacting with immune= pathways (including TLR signaling) that exist in every human. Again, proto= cols don=E2=80=99t split into =E2=80=9Cmen vs women,=E2=80=9D because the g= oal is to shift immune behavior, not set sex-specific hormone levels. =0A= =0ACognition peptides like Semax and Selank? Same story. =0A=0ASemax is lin= ked in research to changes in neurotrophic signaling like BDNF/TrkB, and Se= lank has published work on immune/cytokine modulation in anxious patients. = Those systems don=E2=80=99t require gender dosing by default. =0A=0AEven LL= -37 research shows shared mechanisms like angiogenesis signaling tied to in= nate immunity and wound biology. =0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Final Thou= ghts**=0A=0APeptide dosing is usually the same for men and women because:= =0A=0A1. Most peptides bind to the same receptors in both sexes=0A=0A2. The= goal is to trigger a signal cascade, not =E2=80=9Creplace=E2=80=9D sex hor= mones=0A=0A3. Many peptides hit a threshold where a higher dose gives less = extra benefit=0A=0A4. Real clinical research often uses unified dosing and = watches outcomes, not gender labels=0A=0ANow the exceptions, because there = are always exceptions.=0A=0AIf a peptide or compound causes side effects th= at are consistently more severe in one group, dose titration is warranted. = =0A=0AGLP-1 nausea sensitivity is a common example. Some people need a slow= er ramp. =0A=0AIf someone is very small, very large, has reduced kidney fun= ction, is on other meds that interact, is pregnant, breastfeeding, or has a= complex medical history, you don=E2=80=99t =E2=80=9Cauto-pilot=E2=80=9D do= sing.=0A=0ABut as a general rule? For the major therapeutic peptides, dosin= g is primarily driven by receptor biology and thresholds. That=E2=80=99s wh= y most protocols look the same.=0A=0AAs always, thank you for being a loyal= reader and supporter of my work. =0A=0ABest,=0A=0AHunter Williams=0A=0A=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=0A=0A**Further Reading**=0A=0A* [https://pmc.ncbi.nlm.nih.g= ov/articles/PMC12313605/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605= /)=0A=0A* [https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/](https://pmc.n= cbi.nlm.nih.gov/articles/PMC7747025/)=0A=0A* [https://pubmed.ncbi.nlm.nih.= gov/37110771/](https://pubmed.ncbi.nlm.nih.gov/37110771/)=0A=0A* [https://p= mc.ncbi.nlm.nih.gov/articles/PMC2757071/](https://pmc.ncbi.nlm.nih.gov/arti= cles/PMC2757071/)=0A=0A* [https://www.acpjournals.org/doi/10.7326/0003-4819= -149-9-200811040-00003](https://www.acpjournals.org/doi/10.7326/0003-4819-1= 49-9-200811040-00003)=0A=0A* [https://www.jci.org/articles/view/17545](http= s://www.jci.org/articles/view/17545)=0A=0A* [https://pmc.ncbi.nlm.nih.gov/a= rticles/PMC156109/](https://pmc.ncbi.nlm.nih.gov/articles/PMC156109/)=0A=0A= * [https://pubmed.ncbi.nlm.nih.gov/16996037/](https://pubmed.ncbi.nlm.nih.g= ov/16996037/)=0A=0A* [https://pubmed.ncbi.nlm.nih.gov/18577961/](https://pu= bmed.ncbi.nlm.nih.gov/18577961/)=0A=0A* [https://pubmed.ncbi.nlm.nih.gov/40= 706779/](https://pubmed.ncbi.nlm.nih.gov/40706779/)=0A=0A=0A=E2=80=94=E2=80= =94=E2=80=94=0A=0AYou are reading a plain text version of this post. For th= e best experience, copy and paste this link in your browser to view the pos= t online:=0Ahttps://huntershealthhacks.beehiiv.com/p/men-vs-women-peptide-d= osing --KwbjSenxTCmGujA63/o4UA Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Men vs. Women Peptide Dosing
Does your gender matter?  ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌

January 28, 2026   |   Read Online

Men vs. Women Peptide Dosing

Does your gender = matter?

 
=3D"share
3D"share
 <= a href=3D"https://link.mail.beehiiv.com/v1/c/mogT70hdYu%2B1MHyPq7mZJ%2BKz5s= 4ZOQkQ6mi9xKw7EXs6hPdskcYIZJe%2Fq%2Ffa%0AFG2ekAi5pX5h810uhOoUaAZQcAWOhT6EC1= scRdcctjMi7gFBfFb%2BtKvSLN%2Fv%0Aj0xQFja2c2XR6sHowPTx9SLEAjDSs1gJt%2F9PU671= na9XDWZG7CE%3D%0A/f11abbd18744a844" style=3D"text-decoration:none; display:= block;">
3D"share
 
3D""
= <= tr>= <= /tr><= /tr>

Happy Wednesday!

Today, I will address a question I get pret= ty regularly from readers.

=E2=9D=9D
 

Hunter, why do peptide protocols always seem to use the same dose for m= en and women? Shouldn=E2=80=99t a 220-pound guy take way more than a 130-po= und woman?

Totally fair question, because we=E2=80=99ve all been tr= ained to think dosing =3D body size.

And for some things, that=E2=80=99s true.

But peptides play by a different set of rules than = most people realize.

Most pe= ptides aren=E2=80=99t =E2=80=9Creplacement=E2=80=9D therapies the way testo= sterone, estrogen, progesterone, or thyroid hormone are.

Hormones are more like the gas in your fuel t= ank, whereas peptides are more like tune-ups for every other area of your c= ar.

They bind to receptors, = activate a signal, and trigger downstream cascades. Once you understand tha= t, the unisex dosing makes a lot more sense.

So today, I=E2=80=99ll break down the real reason protocol= s often look identical across men and women, and then I=E2=80=99ll give you= the exceptions so you don=E2=80=99t walk away thinking it=E2=80=99s always= one-size-fits-all.

FYI, <= span style=3D"font-size:1.5rem;">BioL= ongevity Labs is having= a sale. You can get 30% off all products and an extra 15% off with code HU= NTERW.

=  

Receptors=

A GLP-1 receptor doesn= =E2=80=99t have a male version and a female version.

A ghrelin receptor doesn=E2=80=99t change because= someone has higher estrogen.

The =E2=80=9Clock and key=E2=80=9D is the lock and key.

That=E2=80=99s why drugs like retatrutide a= re dosed the same way in men and women in the real world, even though outco= mes can differ slightly (women often lose a bit more weight on average).

That difference isn=E2=80=99t= usually fixed by changing the dose. It=E2=80=99s more about differences in= physiology, appetite signaling, and how body composition shifts over time.=

Same story with growth-hor= mone secretagogues.

When yo= u activate that pathway, you=E2=80=99re telling the pituitary to do what it= already knows how to do. Men and women both have that machinery.

 

Thresholds

This is where people get tripped up. With a lot of peptides, you reach = an effective threshold where receptors are meaningfully activated, and the = cascade is turned on.

After= that, you get diminishing returns fast. More peptide doesn=E2=80=99t alway= s mean more benefit.

Someti= mes it just means more side effects, more water retention, more appetite ch= anges, more cost, more noise.

That=E2=80=99s why =E2=80=9Cstandard=E2=80=9D protocols tend to cluster a= round similar mcg or mg ranges.

They=E2=80=99re trying to hit a practical sweet spot.

Strong enough to create a biological shift, = conservative enough to avoid running the pathway too hard.

You can see this logic in clinical research = too.

In the MK-677 trial in= older adults, a single daily dose was used, growth hormone/IGF-1 levels ro= se, and fat-free mass improved over time, without splitting the protocol in= to =E2=80=9Cmen=E2=80=99s dosing=E2=80=9D and =E2=80=9Cwomen=E2=80=99s dosi= ng.=E2=80=9D

=
 

= Pharmacokinetics

Many people assume that women and men metabol= ize substances differently.

Sometimes that=E2=80=99s true with specific oral drugs, especially when li= ver enzyme differences matter.

But most popular peptides are injected (or nasal), and they=E2=80=99re = cleared by pathways that don=E2=80=99t reliably split by sex in a way that = forces dosing differences.

Instead, what matters more is stuff like:

  • injecti= on route and frequency

  • the half-life of the compound

  • kidney function

  • body fat vs lean mass= distribution

  • = how sensitive the person is to the downst= ream effect (nausea on GLP-1s, edema on GH pathways, etc.)

    • <= /ul>

Peptide dosing has general = =E2=80=9Cparameters=E2=80=9D for both men and women, and then you adjust ba= sed on response.

That=E2= =80=99s why you=E2=80=99ll see slow titrations and conservative ramps in th= e real world, especially with GLP-1s and anything that touches GH/IGF-1.

And again, the clinical data s= upports the idea that outcomes can differ by sex while the dosing protocol = stays the same.

= <= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

And the best human data we have is still limited, bu= t a systematic review covering the broader evidence base notes a small huma= n knee pain series alongside many animal models, with no indication that = =E2=80=9Cfemale tissue needs a different dose.=E2=80=9D

 

Use Cases

Injury repair peptides like BPC-157 are a perfec= t example.

The proposed m= echanism is broadly pro-healing via growth factors, angiogenesis signaling,= inflammation modulation, and tissue remodeling.

Immune peptides are the same concept. <= /p>

Thymosin alpha-1 is used clinically= as an immunomodulator, interacting with immune pathways (including TLR sig= naling) that exist in every human. Again, protocols don=E2=80=99t split int= o =E2=80=9Cmen vs women,=E2=80=9D because the goal is to shift immune behav= ior, not set sex-specific hormone levels.

Cognition peptides like Semax and Selank? Same story.

Semax is linked in research to ch= anges in neurotrophic signaling like BDNF/TrkB, and Selank has published wo= rk on immune/cytokine modulation in anxious patients. Those systems don=E2= =80=99t require gender dosing by default.

Even LL-37 research shows shared mechanisms like angiogenesi= s signaling tied to innate immunity and wound biology.

 

Final Thoughts

Pepti= de dosing is usually the same for men and women because:

  1. Most peptides bind to the same receptor= s in both sexes

  2. The goal is to trigger a signal cascade= , not =E2=80=9Creplace=E2=80=9D sex hormones

  3. Many pepti= des hit a threshold where a higher dose gives less extra benefit

    =

  4. Real clinical research often uses unified dosing and watches outc= omes, not gender labels

Now the exceptions, because there are always exceptions.

If a peptide or compound causes = side effects that are consistently more severe in one group, dose titration= is warranted.

GLP-1 nausea= sensitivity is a common example. Some people need a slower ramp.

If someone is very small, very large= , has reduced kidney function, is on other meds that interact, is pregnant,= breastfeeding, or has a complex medical history, you don=E2=80=99t =E2=80= =9Cauto-pilot=E2=80=9D dosing.

But as a general rule? For the major therapeutic peptides, dosing is pri= marily driven by receptor biology and thresholds. That=E2=80=99s why most p= rotocols look the same.

As a= lways, thank you for being a loyal reader and supporter of my work. =

Best,

Hunter Williams

 =

Further Reading<= /b>

<= /tr><= tr>
3D"ig"3D"yt"
3D""=

Want more? Here=E2=80=99s how you can work with me:

=

=F0=9F=91= =89Join my private coaching group, The AXION Collective:

=F0=9F=91=89Try Zeroats, the world=E2=80=99s first sugar-free,= naturally flavored oatmeal:

=F0=9F=91=89Audio Versions of All Videos:

=F0=9F=91=89Get the Pept= ide Cheat Sheet:

=F0=9F=91=89All my daily essen= tials on Amazon

=F0=9F=91=89Get disco= unts on your favorite peptides and research chemicals:

=F0=9F=91=8910% off the BEST workout supplem= ents from Unmatched Supps (pre-workout, whey protein, creatine, EAAs, elect= rolytes - use code HUNTERW at checkout):

=F0=9F=91=89Submit A Video Topic For= My Next YouTube Video:

Update your email preferences or unsubscr= ibe here

© 2026 Hunter's Health Hac= ks

228 Park Ave S, #29976, New York, New York 10003, United States =

3D"beehiivPow= ered by beehiiv
Terms o= f Service
--KwbjSenxTCmGujA63/o4UA--